Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate

Sodium glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated benefit in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), including slowing the progression of CKD and lowering the risk of kidney failure and death. Despite this evidence, literature suggests SGLT-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chonko, Kayla, Russo-Alvarez, Giavanna, Isaacs, Diana, Wang, Lu, Soric, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653713/
https://www.ncbi.nlm.nih.gov/pubmed/38025173
http://dx.doi.org/10.24926/iip.v14i2.5456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653713/
https://www.ncbi.nlm.nih.gov/pubmed/38025173
http://dx.doi.org/10.24926/iip.v14i2.5456

Ejemplares similares